National Academies Will Meet to Guide 'Gene Editing' Research
By Lisa M. Krieger,
San Jose Mercury News
| 05. 18. 2015
Untitled Document
The debate over human "gene editing" has moved onto the national stage with a prestigious institute announcing it will hold an international summit this fall to create voluntary standards to guide the use of the controversial technology, first conceived by UC Berkeley molecular biologist Jennifer Doudna.
The landmark conference, announced Monday by the Washington, D.C.-based National Academy of Sciences and National Academy of Medicine, will gather researchers and other experts to review and explore the scientific, ethical and social implications of the practice, which can "cut and paste" gene sequences.
Called CRISPR, an acronym for "clustered regularly interspaced short palindromic repeats," Doudna's tool creates the prospect of a future with less sickness -- but could alter future generations -- influencing human evolution by changing the genes in reproductive cells.
The decision to hold a summit follows last month's news that Chinese researchers created the first genetically modified humans, altering nonviable embryos to try to fix the gene defect that causes beta thalassemia, a blood disease.
Doudna and colleagues, including Stanford University bioethicist Hank Greely, last month called for...
Related Articles
By Charles Pulliam-Moore, The Verge | 03.21.2026
Like many people, director Valerie Veatch was intrigued when OpenAI first released its Sora text-to-video generative AI model to the public in 2024. Though she didn’t fully understand the technology, she was curious about what it could do, and she...
By O. Rose Broderick, Stat | 03.18.2026
The Trump administration has zeroed in on its next target: ending health care fraud.
President Trump announced Monday the creation of a task force devoted to ending fraud, waste, and abuse in all federal benefits. On Tuesday, the administration expanded...
By Garrett Owen, Salon | 03.18.2026
By Emily Mullin, Wired | 03.23.2026
As the Trump administration phases out the use of animal experimentation across the federal government, a biotech startup has a bold idea for an alternative to animal testing: nonsentient “organ sacks.”
Bay Area-based R3 Bio has been quietly pitching the...